Display options
Cite
Marconcini R, Spagnolo F, Stucci LS, et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018;9(15):12452-12470doi: 10.18632/oncotarget.23746.
Marconcini, R., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F., Picasso, V., Di Guardo, L., Cimminiello, C., Cavalieri, S., Orgiano, L., Tanda, E., Spano, L., Falcone, A., Queirolo, P. (2018). Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget, 9(15), 12452-12470. https://doi.org/10.18632/oncotarget.23746
Marconcini, Riccardo, et al. "Current status and perspectives in immunotherapy for metastatic melanoma." Oncotarget vol. 9,15 (2018): 12452-12470. doi: https://doi.org/10.18632/oncotarget.23746
Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018 Jan 03;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23. PMID: 29552325; PMCID: PMC5844761.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jan 03;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23.

Current status and perspectives in immunotherapy for metastatic melanoma.

Oncotarget

Riccardo Marconcini, Francesco Spagnolo, Luigia Stefania Stucci, Simone Ribero, Elena Marra, Francesco De Rosa, Virginia Picasso, Lorenza Di Guardo, Carolina Cimminiello, Stefano Cavalieri, Laura Orgiano, Enrica Tanda, Laura Spano, Alfredo Falcone, Paola Queirolo,

Affiliations

  1. Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy.
  2. Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
  3. Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, University of Bari, Bari, Italy.
  4. Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
  5. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST IRCCS, Meldola, Italy.
  6. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  7. AOU Cagliari, Department of Medical Oncology, University of Cagliari, Cagliari, Italy.

PMID: 29552325 PMCID: PMC5844761 DOI: 10.18632/oncotarget.23746

Abstract

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation.

Keywords: immunotherapy; ipilimumab; melanoma; nivolumab; pembrolizumab

Conflict of interest statement

CONFLICTS OF INTEREST R.M. has received payment for consultancy and honoraria for speaking from BMS, MSD, Novartis, Roche. The other authors declare no competing interests.

References

  1. Eur J Cancer. 2016 Sep;65:182-4 - PubMed
  2. Lancet Oncol. 2016 Jul;17(7):943-955 - PubMed
  3. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 - PubMed
  4. J Cell Physiol. 2006 Apr;207(1):58-66 - PubMed
  5. Oncoimmunology. 2015 May 28;4(11):e1046028 - PubMed
  6. Oncoimmunology. 2014 May 14;3:e28780 - PubMed
  7. Curr Opin Immunol. 2015 Apr;33:23-35 - PubMed
  8. N Engl J Med. 2014 Dec 4;371(23):2189-2199 - PubMed
  9. Eur J Cancer. 2017 Apr;75:47-55 - PubMed
  10. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):252-259 - PubMed
  11. Ann Oncol. 2013 Jun;24(6):1697-703 - PubMed
  12. J Immunother. 2012 Oct;35(8):641-9 - PubMed
  13. Ann Oncol. 2015 Apr;26(4):798-803 - PubMed
  14. Melanoma Res. 2011 Dec;21(6):524-9 - PubMed
  15. Anticancer Agents Med Chem. 2010 Nov 1;10(9):661-5 - PubMed
  16. Transl Lung Cancer Res. 2014 Dec;3(6):406-7 - PubMed
  17. J Clin Oncol. 2015 Sep 1;33(25):2780-8 - PubMed
  18. J Clin Invest. 2007 May;117(5):1147-54 - PubMed
  19. Am J Clin Dermatol. 2008;9(5):307-11 - PubMed
  20. Immunity. 2016 May 17;44(5):955-72 - PubMed
  21. N Engl J Med. 2013 Apr 4;368(14):1365-6 - PubMed
  22. J Clin Oncol. 2013 Feb 10;31(5):616-22 - PubMed
  23. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  24. J Immunother Cancer. 2016 Jan 19;4:3 - PubMed
  25. Oncoimmunology. 2016 Feb 18;5(5):e1143997 - PubMed
  26. Cancer. 2015 Nov 1;121(21):3826-35 - PubMed
  27. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  28. Oncoimmunology. 2015 Aug 17;5(7):e1052212 - PubMed
  29. Cancer Immunol Res. 2016 Jul;4(7):569-73 - PubMed
  30. Cancer Immunol Immunother. 2014 Jul;63(7):675-83 - PubMed
  31. Lancet Oncol. 2015 Apr;16(4):375-84 - PubMed
  32. Sci Transl Med. 2015 Mar 18;7(279):279ra41 - PubMed
  33. N Engl J Med. 2011 Jun 2;364(22):2119-27 - PubMed
  34. Cancer Immunol Immunother. 2013 Jun;62(6):1021-8 - PubMed
  35. J Clin Oncol. 2008 Feb 1;26(4):527-34 - PubMed
  36. Pharmacoeconomics. 2015 Dec;33(12):1269-79 - PubMed
  37. Hum Vaccin Immunother. 2016 Oct 2;12(10):2523-2528 - PubMed
  38. J Clin Oncol. 2013 Dec 1;31(34):4311-8 - PubMed
  39. Lancet Oncol. 2012 Sep;13(9):879-86 - PubMed
  40. J Clin Endocrinol Metab. 2014 May;99(5):E832-40 - PubMed
  41. Crit Rev Oncog. 2013;18(6):489-513 - PubMed
  42. Am J Clin Oncol. 2016 Feb;39(1):98-106 - PubMed
  43. Clin Cancer Res. 2015 Feb 15;21(4):712-20 - PubMed
  44. PLoS One. 2014 Feb 03;9(2):e87705 - PubMed
  45. Cancer Res. 2016 Oct 15;76(20):5994-6005 - PubMed
  46. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  47. J Cancer Res Clin Oncol. 1979;95(3):281-6 - PubMed
  48. Br J Cancer. 2016 May 10;114(10):1084-9 - PubMed
  49. Clin Cancer Res. 2011 Feb 15;17(4):896-906 - PubMed
  50. Cancer Immunol Immunother. 2017 Jun;66(6):683-695 - PubMed
  51. Lancet Oncol. 2015 Oct;16(13):1389-98 - PubMed
  52. J Clin Oncol. 2016 Dec;34(34):4102-4109 - PubMed
  53. Clin Cancer Res. 2016 May 1;22(9):2177-82 - PubMed
  54. Cancer Discov. 2016 Aug;6(8):827-37 - PubMed
  55. Ann Oncol. 2017 Feb 1;28(2):368-376 - PubMed
  56. Cancer Immunol Immunother. 2014 May;63(5):449-58 - PubMed
  57. J Clin Oncol. 2014 Jul 20;32(21):2248-54 - PubMed
  58. Cancer. 2007 Dec 15;110(12):2614-27 - PubMed
  59. Nature. 2014 Nov 27;515(7528):568-71 - PubMed
  60. Cancer Res. 2014 Aug 1;74(15):4042-52 - PubMed
  61. Nat Commun. 2016 Jan 29;7:10582 - PubMed
  62. Cancer Res. 1953 Dec;13(12):835-7 - PubMed
  63. Nat Rev Cancer. 2005 May;5(5):397-405 - PubMed
  64. Clin Cancer Res. 2011 Nov 15;17(22):6985-91 - PubMed
  65. Lancet Oncol. 2015 Aug;16(8):908-18 - PubMed
  66. Cancer Immunol Res. 2014 Sep;2(9):831-8 - PubMed
  67. Eur J Cancer. 2015 Sep;51(14):2086-94 - PubMed
  68. Mol Cancer Ther. 2015 Apr;14(4):847-56 - PubMed
  69. Ann Oncol. 2016 Mar;27(3):409-16 - PubMed
  70. Clin Cancer Res. 2015 Jul 15;21(14):3102-4 - PubMed
  71. Immunity. 2007 Jul;27(1):111-22 - PubMed
  72. J Exp Clin Cancer Res. 2014 Apr 04;33:30 - PubMed
  73. Am J Clin Dermatol. 2017 Dec;18(6):745-754 - PubMed
  74. Cancer Treat Rev. 2014 Oct;40(9):1056-64 - PubMed
  75. Br Med J (Clin Res Ed). 1981 May 30;282(6278):1744-5 - PubMed
  76. Ann Oncol. 2016 Apr;27(4):732-8 - PubMed
  77. Hepatogastroenterology. 1983 Jun;30(3):93-5 - PubMed
  78. Crit Rev Oncog. 2013;18(6):573-83 - PubMed
  79. Transl Oncol. 2012 Dec;5(6):404-7 - PubMed
  80. N Engl J Med. 2012 Mar 8;366(10):925-31 - PubMed
  81. Future Oncol. 2016 Dec;12(23):2683-2688 - PubMed
  82. Clin Cancer Res. 2013 Mar 1;19(5):1009-20 - PubMed
  83. J Immunother. 2016 Nov/Dec;39(9):367-372 - PubMed
  84. Br J Dermatol. 2016 Jan;174(1):146-51 - PubMed
  85. Nat Med. 2002 Aug;8(8):793-800 - PubMed
  86. Ann Oncol. 2006 Apr;17(4):563-70 - PubMed
  87. J Clin Oncol. 2016 Apr 20;34(12):1330-8 - PubMed
  88. Cancer Immunol Immunother. 2012 Jul;61(7):1019-31 - PubMed
  89. N Engl J Med. 2017 Oct 5;377(14):1345-1356 - PubMed
  90. Science. 2009 Jan 9;323(5911):220-1 - PubMed
  91. N Engl J Med. 2015 Jul 2;373(1):23-34 - PubMed
  92. Ann Oncol. 2016 Apr;27(4):559-74 - PubMed
  93. J Clin Oncol. 2004 Mar 15;22(6):1118-25 - PubMed
  94. Science. 2015 Apr 3;348(6230):69-74 - PubMed
  95. Ann Oncol. 2013 Oct;24(10):2694-8 - PubMed
  96. Gene Ther. 2005 Feb;12(4):330-8 - PubMed
  97. N Engl J Med. 2011 Jun 30;364(26):2517-26 - PubMed
  98. Radiol Technol. 2016 Sep;88(1):123-8 - PubMed
  99. J Exp Med. 2013 Aug 26;210(9):1695-710 - PubMed
  100. Oncotarget. 2016 Sep 20;7(38):60858-60871 - PubMed
  101. N Engl J Med. 2015 Jun 25;372(26):2521-32 - PubMed
  102. Science. 2016 May 6;352(6286):658-60 - PubMed
  103. Cancer Cell. 2007 Sep;12(3):192-9 - PubMed
  104. Clin Cancer Res. 2016 Oct 1;22(19):4848-4858 - PubMed
  105. Clin Dev Immunol. 2011;2011:469135 - PubMed
  106. Expert Rev Anticancer Ther. 2009 May;9(5):587-95 - PubMed
  107. Pigment Cell Melanoma Res. 2015 Sep;28(5):611-2 - PubMed
  108. J Immunother Cancer. 2014 Feb 18;2:3 - PubMed
  109. J Transl Med. 2010 Jun 11;8:56 - PubMed
  110. Lancet Oncol. 2015 Oct;16(13):e498-509 - PubMed
  111. Nat Med. 2003 Oct;9(10):1269-74 - PubMed
  112. Semin Cancer Biol. 2008 Apr;18(2):111-22 - PubMed
  113. Curr Opin Oncol. 2014 Mar;26(2):204-14 - PubMed

Publication Types